South African biopharmaceutical company Biovac and South Korea-based international non-profit organisation the International Vaccine Institute (IVI) jointly announced in Cape Town on Wednesday that they had concluded a licensing and technology transfer agreement. This agreement, which they described as “ground-breaking”, would allow Biovac to manufacture IVI’s oral cholera vaccine (OCV). “This initiative will be the beginning of end-to-end vaccine manufacture at Biovac, while at the same time addressing an ongoing and increasing cholera disease burden globally,” highlighted Biovac CEO Dr Morena Makhoana. “In addition, this feeds directly into Biovac’s facilities expansion plan to scale up production capacity and will most likely be the first product (drug substance and drug product) to be manufactured in our new facility when it comes on line.”
from Engineering News | Home https://ift.tt/wNa0jrO
